Ocriplasmin
Sponsors
ThromboGenics, Alcon Research
Conditions
Diabetic Macular EdemaExudative Age-Related Macular DegenerationFocal Vitreomacular AdhesionSymptomatic Vitreomacular AdhesionVitrectomyVitreomacular AdhesionVitreomacular Adhesion Including Macular HoleVitreomacular Traction
Phase 2
A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)
CompletedNCT00412451
Start: 2006-12-31End: 2010-03-31Updated: 2014-12-17
A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)
CompletedNCT00435539
Start: 2007-02-28End: 2009-02-28Updated: 2014-12-17
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
CompletedNCT00913744
Start: 2010-01-31End: 2013-04-30Updated: 2014-12-17
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
CompletedNCT00986362
Start: 2010-02-28End: 2012-04-30Updated: 2014-12-17
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
CompletedNCT01159665
Start: 2010-07-31End: 2011-01-31Updated: 2014-12-17
Phase 3
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
CompletedNCT01429441
Start: 2011-10-31End: 2014-10-31Updated: 2016-03-14
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
CompletedNCT01889251
Start: 2013-07-31End: 2014-09-30Updated: 2015-11-30